GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bionano Genomics Inc (NAS:BNGOW) » Definitions » Cash Flow from Financing

Bionano Genomics (Bionano Genomics) Cash Flow from Financing : $77.34 Mil (TTM As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Bionano Genomics Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Mar. 2024, Bionano Genomics received $15.45 Mil more from issuing new shares than it paid to buy back shares. It spent $36.68 Mil paying down its debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It spent $0.39 Mil on other financial activities. In all, Bionano Genomics spent $21.62 Mil on financial activities for the three months ended in Mar. 2024.


Bionano Genomics Cash Flow from Financing Historical Data

The historical data trend for Bionano Genomics's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bionano Genomics Cash Flow from Financing Chart

Bionano Genomics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Financing
Get a 7-Day Free Trial 30.38 61.90 336.11 23.01 113.82

Bionano Genomics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.86 17.88 12.59 68.48 -21.62

Bionano Genomics Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Bionano Genomics's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

Bionano Genomics's Cash from Financing for the quarter that ended in Mar. 2024 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $77.34 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bionano Genomics  (NAS:BNGOW) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Bionano Genomics's issuance of stock for the three months ended in Mar. 2024 was $15.45 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Bionano Genomics's repurchase of stock for the three months ended in Mar. 2024 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Bionano Genomics's net issuance of debt for the three months ended in Mar. 2024 was $-36.68 Mil. Bionano Genomics spent $36.68 Mil paying down its debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Bionano Genomics's net issuance of preferred for the three months ended in Mar. 2024 was $0.00 Mil. Bionano Genomics paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Bionano Genomics's cash flow for dividends for the three months ended in Mar. 2024 was $0.00 Mil. Bionano Genomics received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Bionano Genomics's other financing for the three months ended in Mar. 2024 was $-0.39 Mil. Bionano Genomics spent $0.39 Mil on other financial activities.


Bionano Genomics Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Bionano Genomics's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Bionano Genomics (Bionano Genomics) Business Description

Traded in Other Exchanges
Address
9540 Towne Centre Drive, Suite 100, San Diego, CA, USA, 92121
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in Americas, EMEA and Asia Pacific; majority revenue being generated from Americas.

Bionano Genomics (Bionano Genomics) Headlines

From GuruFocus

Bionano Announces Results from its Annual Meeting of Stockholders

By sperokesalga sperokesalga 06-15-2023